Opus Genetics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IRD research report →
Range $8 – $20
Price Chart
About the company
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders.
- CEO
- George Magrath
- IPO
- 2015
- Employees
- 28
- HQ
- Durham, NC, US
Get TickerSpark's AI analysis on IRD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $331.95M
- P/E
- -2.67
- Fwd P/E
- 10.70
- PEG
- 0.06
- P/S
- 42.89
- P/B
- 10.81
- EV/EBITDA
- -2.13
- Div Yield
- 0.00%
- Gross Margin
- 99.84%
- Op Margin
- -777.66%
- Net Margin
- -1726.70%
- ROE
- 10838.87%
- ROIC
- -72.01%
Latest fiscal year · YoY change
- Revenue
- $14.20M+29.1%
- Gross Profit
- $14.20M+29.1%
- Op Income
- $-38,599,000
- Net Income
- $-49,591,000+13.8%
- EPS
- $-0.80+62.8%
- OCF Growth
- -37.8%
- FCF Growth
- -37.8%
- 52W High
- $7.07
- 52W Low
- $1.86
- 50D MA
- $4.39
- 200D MA
- $4.30
- Beta
- 0.62
- RSI (14)
- 50
- Avg Volume
- 2.56M
No earnings-call transcripts are available for IRD yet.
- Free Float
- 42.4%
- Shares Outstanding
- 83.20M
- Float Shares
- 35.25M
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Held by 93 ETFs
Biggest fund positions in IRD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 3, 26 | Magrath George | sell | 28,258 |
| Oct 23, 26 | SCHACHLE JOSEPH K | sell | 4,767 |
| Oct 23, 26 | YERXA BENJAMIN R | sell | 7,669 |
| Oct 23, 26 | YERXA BENJAMIN R | sell | 25,520 |
| Oct 23, 26 | Gagnon Robert E. | sell | 14,000 |
| Oct 23, 26 | Magrath George | sell | 9,591 |
| Sep 30, 26 | Foundation Fighting Blindness Retinal Degeneration Fund | sell | 556,000 |
| Sep 9, 26 | Magrath George | other | 392,157 |
| Sep 9, 26 | Magrath George | other | 75,541 |
| Sep 9, 26 | Magrath George | other | 392,157 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our IRD coverage
Recent articles, reports, and earnings notes.
No research on IRD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate IRD report →Opus Genetics Announces First Participant Dosed in Phase 1/2 Clinical Trial of OPGx-RDH12 Gene Therapy for Rare Inherited Childhood Blindness
globenewswire.com · Nov 19
Opus Genetics, Inc. (IRD) Reports Q3 Loss, Lags Revenue Estimates
zacks.com · Nov 10
Opus Genetics Announces Financial Results for Third Quarter 2026 and Provides Corporate Update
globenewswire.com · Nov 10
Opus Genetics Completes Dosing in Cohort 2 of Phase 1/2 Clinical Trial of OPGx-BEST1 Gene Therapy for Inherited Retinal Diseases
globenewswire.com · Nov 5
Opus Genetics to Present at the Guggenheim Annual Healthcare Innovation Conference
globenewswire.com · Nov 3
Opus Genetics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
globenewswire.com · Nov 2
Opus Genetics Appoints Dr. Andrew Murphy as Chief Scientific Officer and Jamie Lynne Hart as Executive Director, Executive Operations
globenewswire.com · Oct 29
Opus Genetics Eyes 2029 Runway as Presbyopia Drop Wins FDA Approval
marketbeat.com · Oct 25
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.